People: Genomic Health, Inc. (GHDX.O)
GHDX.O on Consolidated Issue listed on NASDAQ Global Market
16.90USD
10:18am EST
16.90USD
10:18am EST
Price Change (% chg)
$-0.28 (-1.63%)
$-0.28 (-1.63%)
Prev Close
$17.18
$17.18
Open
$17.09
$17.09
Day's High
$17.09
$17.09
Day's Low
$16.79
$16.79
Volume
266,180
266,180
Avg. Vol
223,918
223,918
52-wk High
$27.22
$27.22
52-wk Low
$15.81
$15.81
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Scott, Randal | 51 | 2009 | Executive Chairman of the Board |
| Popovits, Kimberly | 50 | 2009 | President, Chief Executive Officer, Director |
| Cole, G. Bradley | 53 | 2009 | Chief Financial Officer, Chief Operating Officer, Secretary |
| Baker, Joffre | 61 | 2000 | Chief Scientific Officer |
| Shak, Steven | 58 | 2000 | Chief Medical Officer |
| Baker, Julian | 42 | 2001 | Director |
| Byers, Brook | 63 | 2001 | Director |
| Cohen, Fred | 52 | 2002 | Director |
| Colella, Samuel | 69 | 2001 | Director |
| Livingston, Randall | 55 | 2004 | Director |
| Myers, Woodrow | 55 | 2006 | Director |
| Graham, Ginger | 53 | 2008 | Director |
Biographies
| Name | Description |
|---|---|
| Scott, Randal | Dr. Randal W. Scott, Ph.D., is Executive Chairman of the Board of Genomic Health, Inc. since January 2009, Chairman of the Board and Chief Executive Officer since the inception in August 2000 until December 2008, President from August 2000 until February 2002, Chief Financial Officer from December 2000 until April 2004, and Secretary from August 2000 until December 2000 and from May 2003 until February 2005. Dr. Scott was a founder of Incyte Corporation, a genomic information company, and served Incyte in various roles, including Chairman of the Board from August 2000 to December 2001, President from January 1997 to August 2000, and Chief Scientific Officer from March 1995 to August 2000. Dr. Scott holds a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas. |
| Popovits, Kimberly | Kimberly J. Popovits is President, Chief Executive Officer since since January 2009, Director since March 2002 of Genomic Health, Inc. She was President and Chief Operating Officer since February 2002. From November 1987 to February 2002, Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, she served as Division Manager, Southeast Region, for American Critical Care, a division of American Hospital Supply, a supplier of health care products to hospitals. Ms. Popovits holds a B.A. in Business from Michigan State University. |
| Cole, G. Bradley | G. Bradley Cole is Chief Operating Officer and Chief Financial Officer of Genomic Health, Inc. since January 2009, Executive Vice President, Operations from January 2008 until December 2008, Executive Vice President and Chief Financial Officer from July 2004 until December 2008 and Secretary since February 2005. From December 1997 to May 2004, he served in various positions at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group from January 2001 until May 2004. From July 1994 to December 1997, Mr. Cole was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation. From December 1988 to February 1994, he served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Mr. Cole holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University. |
| Baker, Joffre | Dr. Joffre B. Baker, Ph.D., is Chief Scientific Officer of Genomic Health, Inc. since December 2000. From March 1997 to October 2000, Dr. Baker served as the Vice President for Research Discovery at Genentech. From March 1993 to October 2000, Dr. Baker oversaw Research Discovery at Genentech, which included the departments of Cardiovascular Research, Oncology, Immunology, Endocrinology, and Pathology. From July 1991 to October 1993, he served as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech, Dr. Baker was a member of the faculty of the Department of Biochemistry at the University of Kansas. He holds a B.S. in Biology and Chemistry from the University of California, San Diego and a Ph.D. in Biochemistry from the University of Hawaii. |
| Shak, Steven | Dr. Steven Shak, M.D., is Chief Medical Officer of Genomic Health, Inc. since December 2000. From July 1996 to October 2000, Dr. Shak served in various roles in Medical Affairs at Genentech, most recently as Senior Director and Staff Clinical Scientist. From November 1989 to July 1996, Dr. Shak served as a Director of Discovery Research at Genentech, where he was responsible for Pulmonary Research, Immunology, and Pathology. Prior to joining Genentech, Dr. Shak was an Assistant Professor of Medicine and Pharmacology at the New York University School of Medicine. Dr. Shak holds a B.A. in Chemistry from Amherst College and an M.D. from the New York University School of Medicine, and completed his post-doctoral training at the University of California, San Francisco. |
| Baker, Julian | Julian C. Baker is Director of Genomic Health, Inc. He is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston. He is also a director of Incyte Corporation, Neurogen Corporation and Trimeris, Inc. Mr. Baker holds an A.B. in Social Studies from Harvard University. |
| Byers, Brook | Brook H. Byers is Director of Genomic Health, Inc. He is a general partner of Kleiner Perkins Caufield & Byers, a venture capital firm which he joined in 1977. Mr. Byers currently serves as a director of a number of privately held technology, healthcare and biotechnology companies. Mr. Byers holds a B.S. in Electrical Engineering from the Georgia Institute of Technology and an M.B.A. from the Stanford Graduate School of Business. |
| Cohen, Fred | Dr. Fred E. Cohen, M.D., Ph.D. is Director of Genomic Health, Inc. He is a partner at TPG, a private equity firm he joined in 2001, and serves as co-head of TPG’s biotechnology group. Dr. Cohen is also a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, where he has taught since 1988. Dr. Cohen is a director of Matrix Laboratories Limited, Quintiles Transnational and a number of privately held companies. Dr. Cohen holds a B.S. in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford University and an M.D. from Stanford University. |
| Colella, Samuel | Samuel D. Colella is Director of Genomic Health, Inc. He co-founded Versant Ventures, a healthcare and biotechnology venture capital firm, in 1999. Mr. Colella is also a general partner of Institutional Venture Partners, a venture capital firm he joined in 1984. Mr. Colella currently serves as a director of Alexza Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc. and a number of privately held technology and biotechnology companies. Mr. Colella has a B.S. in Business and Engineering from the University of Pittsburgh and an M.B.A. from the Stanford Graduate School of Business. |
| Livingston, Randall | Randall S. Livingston is Director of Genomic Health, Inc. He has served as Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001. From 1999 to 2001, Mr. Livingston served as Executive Vice President and Chief Financial Officer of OpenTV Corp., a provider of interactive television services. From 1996 until 1999, Mr. Livingston served as a consultant and part-time executive for several Silicon Valley technology companies. Prior to 1996, Mr. Livingston worked for Heartport, Inc., Taligent, Apple Computer, Ingres Corporation and McKinsey & Company. Mr. Livingston currently serves as a director of eHealth, Inc. Mr. Livingston holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business. |
| Myers, Woodrow | Dr. Woodrow A. Myers, Jr., M.D., is Director of Genomic Health, Inc. He has served as Managing Director of Myers Ventures LLC, which concentrates on opportunities in healthcare and education, since December 2005. He was the Executive Vice President and Chief Medical Officer of WellPoint, Inc., a commercial health benefits company, from September 2000 to January 2005. Dr. Myers currently serves on the board of directors of CardioNet, Inc., Express Scripts, Inc. and ThermoGenesis Corp. Dr. Myers holds a B.S. in Biological Sciences from Stanford University, an M.D. from Harvard Medical School and an M.B.A. from the Stanford University Graduate School of Business. |
| Graham, Ginger | Ginger L. Graham is Director of Genomic Health, Inc. She is President and Chief Executive Officer of Two Trees Consulting, a healthcare and executive leadership consulting firm, since November 2007. From September 2003 to March 2007, Ms. Graham was the Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company, and she served as Amylin’s President from September 2003 to June 2006. Prior to joining Amylin, Ms. Graham held various positions with Guidant Corporation, including Group Chairman, Office of the President, President of the Vascular Intervention Group, and Vice President. Ms. Graham held various positions with Eli Lilly and Company from 1979 to 1992, including sales, marketing, finance and strategic planning positions. She currently serves as a director of Amylin Pharmaceuticals, Inc. and a number of privately held companies. Ms. Graham holds a B.S. in Agricultural Economics from University of Arkansas and an M.B.A. from Harvard University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Scott, Randal | 697,800 |
| Popovits, Kimberly | 803,450 |
| Cole, G. Bradley | 761,700 |
| Baker, Joffre | 768,250 |
| Shak, Steven | 778,100 |
| Baker, Julian | -- |
| Byers, Brook | -- |
| Cohen, Fred | -- |
| Colella, Samuel | -- |
| Livingston, Randall | -- |
| Myers, Woodrow | -- |
| Graham, Ginger | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Scott, Randal | 188,696 | 1,723,960 |
| Popovits, Kimberly | 206,037 | 1,684,749 |
| Cole, G. Bradley | 243,370 | 1,985,599 |
| Baker, Joffre | 119,348 | 631,760 |
| Shak, Steven | 119,348 | 631,760 |
| Baker, Julian | 0 | 0 |
| Byers, Brook | 0 | 0 |
| Cohen, Fred | 0 | 0 |
| Colella, Samuel | 0 | 0 |
| Livingston, Randall | 0 | 0 |
| Myers, Woodrow | 0 | 0 |
| Graham, Ginger | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| COLE GORDON BRADLEY | 5,000 | $1.33 |
| COLE GORDON BRADLEY | 5,000 | $17.25 |
| BAKER JOFFRE B | 4,629 | $17.47 |
| SHAK STEVEN | 5,000 | $20.12 |
| COLE GORDON BRADLEY | 2,000 | $20.42 |
| SCOTT RANDAL W | 6,000 | $20.22 |
| SCOTT RANDAL W | 6,000 | $20.27 |
| BAKER JOFFRE B | 4,629 | $20.26 |
| POPOVITS KIMBERLY J | 15,000 | $19.19 |
| POPOVITS KIMBERLY J | 5,000 | $19.26 |
| COLE GORDON BRADLEY | 665 | $20.04 |
| COLE GORDON BRADLEY | 665 | $1.33 |
| SCOTT RANDAL W | 6,000 | $19.98 |
| BAKER JOFFRE B | 4,629 | $20.00 |
| SCOTT RANDAL W | 6,000 | $20.00 |
| SHAK STEVEN | 5,000 | $20.65 |
| POPOVITS KIMBERLY J | 5,000 | $20.42 |
| SCOTT RANDAL W | 6,000 | $20.36 |
| SCOTT RANDAL W | 6,000 | $20.96 |
| BAKER JOFFRE B | 4,629 | $21.17 |
| SHAK STEVEN | 5,000 | $21.13 |
| POPOVITS KIMBERLY J | 5,000 | $20.73 |
| SCOTT RANDAL W | 6,000 | $20.63 |
| SCOTT RANDAL W | 6,000 | $20.72 |
| BAKER JOFFRE B | 4,629 | $20.12 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
